Funded Biotechnology Startups in Italy
Among the 25 most recent biotech rounds in Italy, the largest disclosed amount is Sibylla Biotech’s $23M Series A (2022-10-04).
Among the 25 most recent biotech rounds in Italy, the largest disclosed amount is Sibylla Biotech’s $23M Series A (2022-10-04). That figure is materially above the next tier of disclosed deals (for example, Kither Biotech $20M on 2022-03-16 and PHSE $17M on 2024-10-01), while several other disclosed rounds sit at or below $5M (e.g., NOUS Energy $350K on 2024-09-30; Diamante $640K on 2023-01-17). Date-wise, the list spans 2020-05-07 (PinCell s.r.l.) to 2026-04-01 (BM Diagnostics), with a noticeable concentration of disclosed rounds between 2024-09-30 and 2025-10-26 (PHSE, MOGU, Yeastime, Genenta Science). Geographically, Lombardia shows up repeatedly (Genenta Science 2025-10-26, PHSE 2024-10-01, MOGU 2024-01-09, plus others), suggesting cluster behavior rather than evenly distributed locations.
Most recent rounds
25 shownRelated listings
Frequently asked
What’s the largest disclosed biotech round in this Italy slice, and is it a true outlier?
Sibylla Biotech’s $23M Series A on 2022-10-04 is the top disclosed amount in the 25-row view, with the next-largest disclosed rounds trailing at $20M (Kither Biotech, 2022-03-16) and $17M (PHSE, 2024-10-01). Several other disclosed deals are far smaller, including $1M rounds like Oraigo (2025-07-24) and Composite Research (2024-10-07).
Do these recent biotech rounds cluster into a narrow time window?
Yes. A dense run of rounds appears from late 2024 through 2025: PHSE ($17M) on 2024-10-01, NOUS Energy ($350K) on 2024-09-30, Yeastime ($1M) on 2025-09-08, and Genenta Science ($15M) on 2025-10-26. In contrast, the oldest dated entry in the set is PinCell s.r.l. with $2M on 2020-05-07.
Which locations appear most consistently across the disclosed entries?
Lombardia is the most visible hub in this table, with multiple entries in Milan or nearby cities: Genenta Science (Milano, $15M on 2025-10-26), PHSE (Lodi, $17M on 2024-10-01), MOGU (Varese, $12M on 2024-01-09), and GFBiochemicals (Milan, $16M on 2022-05-05). That repetition contrasts with one-off cities like Cantiano (BM Diagnostics, 2026-04-01, undisclosed).
How much of the activity has undisclosed or “Series Unknown” funding labels?
Across the 25 rows, there are 3 entries marked as undisclosed amounts (BM Diagnostics on 2026-04-01; Resalis Therapeutics on 2024-10-28; Diatech Pharmacogenetics on 2023-04-26) and 5 entries labeled “Series Unknown” (Genenta Science 2025-10-26; Yeastime 2025-09-08; Genoa Instruments 2025-02-05; GFBiochemicals is Series A; plus PHSE is Series Unknown on 2024-10-01; and Genenta Science again—counted once per row). The result is that series clarity is missing for a meaningful share of the most recent deals.
Which stage names dominate, and where do they show up in larger rounds?
Series A appears multiple times with larger disclosed checks, including Sibylla Biotech ($23M on 2022-10-04), MOGU ($12M on 2024-01-09), Sensosan ($3M on 2022-09-01), and GFBiochemicals ($16M on 2022-05-05). Seed also shows up often (e.g., FTnet $5M on 2025-07-02; Oraigo $1M on 2025-07-24; Composite Research $1M on 2024-10-07), but these disclosed seed rounds generally fall below the Series A ceiling set by Sibylla Biotech.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.